{"ticker": {"uuid": "df4e87f2-c9fc-45b3-9aff-1e0419d59a3c", "symbol": "KPRX", "name": "Kiora Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. \u2013 LS:A40EG5", "summary": "This article focuses on the enterprise value to revenue forward for Kiora Pharmaceuticals, Inc. (LS:A40EG5). It presents no specific data but indicates where one might find such financial information and related news on the TradingView platform.", "url": "https://www.tradingview.com/symbols/LS-A40EG5/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T02:40:50", "published_display": "11 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc. (KPRX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Kiora Pharmaceuticals Inc. (KPRX) stock. It includes current stock price, basic charting options, and a note indicating no analyst ratings or earnings information currently available. The article also contains extensive disclaimers ab", "url": "https://timothysykes.com/quote/KPRX/", "source_name": "timothysykes.com", "published_at": "2026-07-10T00:43:26", "published_display": "10 Jul 2026 00:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. \u2013 GETTEX:7EY", "summary": "This article provides financial information for Kiora Pharmaceuticals, Inc. (GETTEX:7EY), specifically focusing on its enterprise value to revenue forward. It appears to be a stub or a data point from a financial platform like TradingView, indicating no extensive textual analysis", "url": "https://www.tradingview.com/symbols/GETTEX-7EY/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T12:11:09", "published_display": "07 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Kiora Pharmaceuticals, Inc. \u2013 NASDAQ:KPRX", "summary": "The article focuses on Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) and presents its \"Price to book forward\" financial metric. It appears to be a stub or a section of a larger financial data page on TradingView, indicating that the value for this specific metric is missing or not pr", "url": "https://www.tradingview.com/symbols/NASDAQ-KPRX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T16:40:46", "published_display": "05 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Kiora Pharmaceuticals, Inc. \u2013 NASDAQ:KPRX", "summary": "This article provides financial information for Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) on TradingView, specifically focusing on its enterprise value to forward EBIT. The content indicates that the market for KPRX was closed with no trades at the time of publication. It highlig", "url": "https://www.tradingview.com/symbols/NASDAQ-KPRX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T13:11:18", "published_display": "05 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPRX - Kiora Pharmaceuticals Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information and detailed financial data for Kiora Pharmaceuticals Inc. (KPRX). Key metrics include its market capitalization, enterprise value, income, sales, per-share values, dividend information, and various financial ratios, alongsi", "url": "https://finviz.com/stock?t=KPRX&ty=lf&page=6", "source_name": "Finviz", "published_at": "2026-07-05T04:41:17", "published_display": "05 Jul 2026 04:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Kiora Pharmaceuticals Inc For: 2 July By Investing.com", "summary": "This article announces the filing of Form 4 for Kiora Pharmaceuticals Inc on July 2nd. It provides key financial data for several indices, commodities, and individual stocks, along with various market news headlines. The content also features sections on trending stocks, market m", "url": "https://in.investing.com/news/stock-market-news/form-4-kiora-pharmaceuticals-inc-for-2-july-93CH-5481454", "source_name": "Investing.com India", "published_at": "2026-07-03T02:22:00", "published_display": "03 Jul 2026 02:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora (NASDAQ: KPRX) CFO uses 911 shares to cover tax obligations", "summary": "Kiora Pharmaceuticals' CFO, Melissa Tosca, reported a tax-withholding disposition of 911 shares of common stock at $2.66 per share on July 1, 2026. This transaction was to cover tax obligations and not an open-market sale. Following this, Tosca directly holds 26,064 KPRX shares.", "url": "https://www.stocktitan.net/sec-filings/KPRX/form-4-kiora-pharmaceuticals-inc-insider-trading-activity-768d87cf95c0.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:10:20", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] KIORA PHARMACEUTICALS INC Insider Trading Activity", "summary": "Kiora Pharmaceuticals' President and CEO, Brian M. Strem, reported a tax-related disposition of 1,869 common shares on July 1, 2026, at a price of $2.66 per share. This transaction was for withholding tax obligations and not an open market sale. Following this adjustment, Strem d", "url": "https://www.stocktitan.net/sec-filings/KPRX/form-4-kiora-pharmaceuticals-inc-insider-trading-activity-a7feaa8def25.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:10:20", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium", "summary": "Kiora Pharmaceuticals announced its participation in the Piper Sandler Virtual Ophthalmology Symposium, featuring an investor fireside chat on July 9, 2026. The clinical-stage biotechnology company focuses on developing advanced therapies for retinal diseases, including KIO-301 f", "url": "https://finance.yahoo.com/healthcare/articles/kiora-pharmaceuticals-participate-piper-sandler-110000041.html", "source_name": "Market source", "published_at": "2026-07-02T18:10:19", "published_display": "02 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora set for Piper Sandler fireside chat on July 9", "summary": "Kiora Pharmaceuticals (NASDAQ:KPRX) will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium on Thursday, July 9, 2026, at 2:30 p.m. EDT. The presentation will be webcast live and a replay will be available for 90 days on Kiora's Investor", "url": "https://www.stocktitan.net/news/KPRX/kiora-pharmaceuticals-to-participate-in-piper-sandler-virtual-ey361aw245yf.html", "source_name": "Stock Titan", "published_at": "2026-07-02T11:12:23", "published_display": "02 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc Warrant 2022-27.09.27 on Kiora Pharma A Financial Disclosures & SEC Filings", "summary": "This page provides access to financial disclosures and SEC filings for Kiora Pharmaceuticals, Inc. (KPHMW), including Forms 10-K, 10-Q, 8-K, and other key documents. The content highlights the company's financial performance, operational updates, clinical trial progress, and corp", "url": "https://www.tradingview.com/symbols/OTC-KPHMW/documents/", "source_name": "TradingView", "published_at": "2026-07-01T22:40:29", "published_display": "01 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPRX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price forecast and current statistics for Kiora Pharmaceuticals, Inc. (KPRX). Analysts have set a price target range of $12.00, with varied recommendations for the stock. The article also covers KPRX's current stock price dynamics, historical highs and low", "url": "https://www.tradingview.com/symbols/NASDAQ-KPRX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T13:10:42", "published_display": "26 Jun 2026 13:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:KPRX)", "summary": "This article provides an overview of Kiora Pharmaceuticals, Inc. (KPRX) stock, including current price, historical performance, analyst forecasts, and financial estimates. It highlights key financial data, such as market capitalization, earnings per share, and net income, and con", "url": "https://www.tradingview.com/symbols/NASDAQ-KPRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:11:41", "published_display": "26 Jun 2026 09:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "7EY Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Kiora Pharmaceuticals, Inc. (7EY) on the Frankfurt Stock Exchange. It details analyst opinions, past performance data, financial reports, and answers frequently asked questions about the company's stock, including earnings, ne", "url": "https://www.tradingview.com/symbols/FWB-7EY/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:45", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc (KPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Kiora Pharmaceuticals Inc (KPRX), detailing its price momentum score of 6.44 and its ranking within the Biotechnology & Medical Research industry. It identifies current support and resistance levels at $2.36 and $2.81, respectively, s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kprx/technical", "source_name": "TradingKey", "published_at": "2026-06-22T12:10:46", "published_display": "22 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX)", "summary": "The article highlights bullish sentiments from analysts on three healthcare stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX), and Luye Pharma Group (LYPHF). Guoyuan Securities (HK) Ltd maintained a Buy rating for Ascentage Pharma with a HK$43.7", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2570678/analysts-are-bullish-on-top-healthcare-stocks-ascentage-pharma-group-international-hk6855-kiora-pharmaceuticals-kprx/", "source_name": "The Globe and Mail", "published_at": "2026-06-21T09:16:56", "published_display": "21 Jun 2026 09:16", "sentiment": "positive", "sentiment_pct": 85, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model", "summary": "Kiora Pharmaceuticals announced preclinical data showing that its ion channel modulator, KIO-300, significantly suppressed seizure activity in an ex vivo temporal lobe epilepsy model. These findings, presented at the Epilepsy Foundation Pipeline Conference, suggest the platform h", "url": "https://ca.finance.yahoo.com/news/kiora-pharmaceuticals-reports-ion-channel-110000045.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-19T12:10:46", "published_display": "19 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPRX SEC Filings - KIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms", "summary": "This page provides access to KIORA PHARMACEUTICALS (KPRX) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-generated summaries and sentiment analysis. Recent filings include the Q3 2025 10-Q reporting a small net income and strong liquidity, and several Schedule 13G/A fi", "url": "https://www.stocktitan.net/sec-filings/KPRX/page-4.html", "source_name": "Stock Titan", "published_at": "2026-06-19T11:39:05", "published_display": "19 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals\u2019 KIO-300 Shows Significant Seizure Suppression in Preclinical Epilepsy Model, Revealing Potential Beyond Ophthalmology 1 \u2013 Minichart", "summary": "Kiora Pharmaceuticals announced significant preclinical results for KIO-300, demonstrating its ability to suppress seizure activity in an ex vivo temporal lobe epilepsy model. These findings suggest KIO-300, initially developed for retinal diseases, has potential in neurological ", "url": "https://www.minichart.com.sg/2026/06/18/kiora-pharmaceuticals-kio-300-shows-significant-seizure-suppression-in-preclinical-epilepsy-model-revealing-potential-beyond-ophthalmology-1/", "source_name": "Minichart", "published_at": "2026-06-18T15:09:15", "published_display": "18 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc (KPRX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Kiora Pharmaceuticals Inc (KPRX), outlining its major shareholders, their proportion of holdings, and institutional investment trends. Key shareholders include Adar1 Capital Management LLC and Stonepine Capital Management, LLC, wh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kprx/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T14:10:38", "published_display": "18 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora's KIO-300 cut epileptiform activity in epilepsy model", "summary": "Kiora Pharmaceuticals (NASDAQ: KPRX) announced preclinical data indicating its ion channel modulator, KIO-300, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model. These findings were presented at the Epilepsy Found", "url": "https://www.stocktitan.net/news/KPRX/kiora-pharmaceuticals-reports-its-ion-channel-modulator-kio-300-r1wyrtnaj3pz.html", "source_name": "Stock Titan", "published_at": "2026-06-18T11:09:15", "published_display": "18 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals (NASDAQ: KPRX) reports KIO-300 epilepsy model data", "summary": "Kiora Pharmaceuticals announced preclinical data for its ion channel modulator, KIO-300, showing it significantly suppressed seizure activity in an ex vivo temporal lobe epilepsy model. This finding suggests potential applications for KIO-300, the active ingredient in its Phase 2", "url": "https://www.stocktitan.net/sec-filings/KPRX/8-k-kiora-pharmaceuticals-inc-reports-material-event-cbb82fe0bb33.html", "source_name": "Stock Titan", "published_at": "2026-06-18T11:09:15", "published_display": "18 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc (KPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Kiora Pharmaceuticals Inc (KPRX) has an earnings forecast score of 8.00, ranking 165 out of 389 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $12.00, indicating a significant upside. The company's expected revenue for the next quar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kprx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:30", "published_display": "18 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc (KPRX) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis of Kiora Pharmaceuticals Inc (KPRX), noting its current valuation score is 8.69, ranking 104 out of 388 in its industry. It highlights the company's P/E ratio of -0.97 but also states that data for P/B, P/S, and P/CF ratios have not yet b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kprx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:15", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc (KPRX) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Kiora Pharmaceuticals Inc (KPRX), which is currently 3.00, unchanged from its previous score. It lists several institutional shareholders and their recent changes in shares held, indicating varying levels of ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kprx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T07:09:15", "published_display": "18 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc (KPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Kiora Pharmaceuticals Inc (KPRX), focusing on business segments and regional contributions. However, it states that relevant data for FY2025 (including Q1, Q2, Q3) and FY2024, FY2021, FY2020, FY2019 have not yet been disclosed by the ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kprx/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T03:40:58", "published_display": "18 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc (KPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Kiora Pharmaceuticals Inc (KPRX). It notes that KPRX has not distributed any dividends over the past five years. The article primarily details multiple stock merger events, specifically 9-to-1 mergers in Ju", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kprx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:58", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals (NASDAQ: KPRX) director receives stock options for 25,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNY3JZLXZ1SlY4TFdmdTBqOVd6aTdHNUUxdlVmWExELUZ4azRWUHlBdm50ZkJLMTF1LVZJM2VVRjF0M2V3dmxKbDhEUDJHU2RuN1BkamZsX0hDY0s0eXRsa1lwQ3FBTVByOVU2ZW1OY2N1TXM1LVNKallkNWE5VllWSl9iS1RQbFUxdDVhM2k4YW1Qd3pBT0VTZEJBVTRpcUFabkdGb05WQWFLZ3U2dXJTd3BYSG93d1V3RVA4?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals (KPRX) Slips 4.9% as Stock Tests Key Support Levels - Imbalance Zone", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPRDgtRGdUdDZXb2oxNHJPaFBWMGFzcXU2cWZNWlROcE9pMW5yNThXSnprcWM0STBXNHFyYW1oYS05em44NS1KUlRNY2xhY1RlbjJwVWZNREl4ZzFuaXM2aGU4aHd4bk5PaEpsUUlDMGE5aml6VWZycFJMeG9SR1dVMk5xTXpwMGsxUTVabENxQ25LSVliRXMwbTBKTkZ4SGRESThzWlk3YWtYWkxnOW9wd1BlRGZOMjNHMWc?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals (KPRX) Rallies 5.5%: Key Levels to Watch After Recent Uptick - IV Spike", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOWG1wMnBnRHk4N2Q5UG1MbzQ2dTN6SjNvRVJScG85LTJBRUxnbldLLV8yM2JlQXlwQjJQb1FPR29RSEl1NlFIR1h1dzNfY0FWdGhwSGJPZW5oMW5HZkNOUUtteWtHXzRnNzJHcWJUTGlUY2VwMUFNdTA4ZnBFNGJMekJma1NrdDd6YWFudG91SEk5bDNBdTQxVG1EcG1kTFdkM3hsVVVRZTlWUnJTUkllcEZIa3hXcEhFQjFUSzlR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kiora-pharmaceuticals-reports-first-quarter-110000128.html", "source_name": "TMX Newsfile", "published_at": "2026-05-08T11:00:00+00:00", "published_display": "08 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPbHM0bDg5c3V1OG9iOTFLSUdlNm9CeVVmX25YN0Zvel9HcDhuY3BVSnlVY3lqMFVqYThGSVdvWWxLR3ppeEs0eWFoa0Fhc3Y0R3NUSy14MkR3Mk9hcmdIZGtucmZ3M19Pb2FYODhrbWhURjhmbHMzSGhaY2pYV3hNMExTZVVRWFpaMjF2QVhpZXhWX1cwX3N1QW0zRDAya19MZHhaS1VGRXRrRmZGaDRHc2Frc1dYa292cTFXWnhOV0otdHg0UVFhN1ZCdncteENEbWw2N3NMQ0s?oc=5", "source_name": "TMX Newsfile", "published_at": "2026-04-07T11:12:10+00:00", "published_display": "07 Apr 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals\u2019 Stock Analysis amidst Financial Challenges", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOdjBMNTRHbEZpcG9CbXZHSWtWbjNfZ25tNUZ5T2lCTVI4YTgyTnZJUFdKNmkzX3d2UVFDb3ZZVVBrQUtHc3pVVkRMN0daOUI3emtMQk9tVDl4UUtJWW9iUEJvQWpNdVo1YUYxMzVRSmpQNWZ1Z1ZBRlV2dDI3Z3FGMHgtZzM?oc=5", "source_name": "StocksToTrade", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "KPRX Stock Price and Chart \u2014 NASDAQ:KPRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1fS2dxY0tIUmJBXzRZTnlzSml1MGxXQnQwQ3djYlBlamwxcExwS3ppcWtfMlhMaWhRbUdhM1ljRmctS3JiVlNsdFk0b2VVNU9oSEZ1b0o4VnE0M0hR?oc=5", "source_name": "TradingView", "published_at": "2024-06-20T07:00:00+00:00", "published_display": "20 Jun 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQb2Q2bUxmV2lRaWNkUG55R0xHUEJuMlJnTUkzUWZxRzcyYVVnLVhvUWpfWVl2TUFxUU5Fc19sb1ZuYjlGaXY1aUlQUWhOQXhsMjc5RUY3elV2OHI5bTRXVl9BdEtIUjhqbWJCcEZwMDl3dUJGaDFIUno2MWNKVXE2aFFUdkgxc2VNSVEtQjRpUmVJU2FUTF8yZmFnQ0RDV1BmTWVJQ0pDTGpvUXZVUTBwMHd5a3ItRHF2Ny1BS054MG0wdUhiZkE?oc=5", "source_name": "TMX Newsfile", "published_at": "2024-01-31T08:00:00+00:00", "published_display": "31 Jan 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE0wV2trWmVfaWJMMGEzMkNlZGtnbjdVa0Y3aDF4UW5NMU12anhPNENBWFB3a2pIbHhVamV6UDE5ZEtQeE9wT3h1aTQ1Ymt2TldrLUVxVHdtVW8tQQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-11-16T10:15:41+00:00", "published_display": "16 Nov 2021 10:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. \u2013 LS:A40EG5", "summary": "This article focuses on the enterprise value to revenue forward for Kiora Pharmaceuticals, Inc. (LS:A40EG5). It presents no specific data but indicates where one might find such financial information and related news on the TradingView platform.", "url": "https://www.tradingview.com/symbols/LS-A40EG5/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T02:40:50", "published_display": "11 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc. (KPRX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Kiora Pharmaceuticals Inc. (KPRX) stock. It includes current stock price, basic charting options, and a note indicating no analyst ratings or earnings information currently available. The article also contains extensive disclaimers ab", "url": "https://timothysykes.com/quote/KPRX/", "source_name": "timothysykes.com", "published_at": "2026-07-10T00:43:26", "published_display": "10 Jul 2026 00:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. \u2013 GETTEX:7EY", "summary": "This article provides financial information for Kiora Pharmaceuticals, Inc. (GETTEX:7EY), specifically focusing on its enterprise value to revenue forward. It appears to be a stub or a data point from a financial platform like TradingView, indicating no extensive textual analysis", "url": "https://www.tradingview.com/symbols/GETTEX-7EY/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T12:11:09", "published_display": "07 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Kiora Pharmaceuticals, Inc. \u2013 NASDAQ:KPRX", "summary": "The article focuses on Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) and presents its \"Price to book forward\" financial metric. It appears to be a stub or a section of a larger financial data page on TradingView, indicating that the value for this specific metric is missing or not pr", "url": "https://www.tradingview.com/symbols/NASDAQ-KPRX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T16:40:46", "published_display": "05 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Kiora Pharmaceuticals, Inc. \u2013 NASDAQ:KPRX", "summary": "This article provides financial information for Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) on TradingView, specifically focusing on its enterprise value to forward EBIT. The content indicates that the market for KPRX was closed with no trades at the time of publication. It highlig", "url": "https://www.tradingview.com/symbols/NASDAQ-KPRX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T13:11:18", "published_display": "05 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPRX - Kiora Pharmaceuticals Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information and detailed financial data for Kiora Pharmaceuticals Inc. (KPRX). Key metrics include its market capitalization, enterprise value, income, sales, per-share values, dividend information, and various financial ratios, alongsi", "url": "https://finviz.com/stock?t=KPRX&ty=lf&page=6", "source_name": "Finviz", "published_at": "2026-07-05T04:41:17", "published_display": "05 Jul 2026 04:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Kiora Pharmaceuticals Inc For: 2 July By Investing.com", "summary": "This article announces the filing of Form 4 for Kiora Pharmaceuticals Inc on July 2nd. It provides key financial data for several indices, commodities, and individual stocks, along with various market news headlines. The content also features sections on trending stocks, market m", "url": "https://in.investing.com/news/stock-market-news/form-4-kiora-pharmaceuticals-inc-for-2-july-93CH-5481454", "source_name": "Investing.com India", "published_at": "2026-07-03T02:22:00", "published_display": "03 Jul 2026 02:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora (NASDAQ: KPRX) CFO uses 911 shares to cover tax obligations", "summary": "Kiora Pharmaceuticals' CFO, Melissa Tosca, reported a tax-withholding disposition of 911 shares of common stock at $2.66 per share on July 1, 2026. This transaction was to cover tax obligations and not an open-market sale. Following this, Tosca directly holds 26,064 KPRX shares.", "url": "https://www.stocktitan.net/sec-filings/KPRX/form-4-kiora-pharmaceuticals-inc-insider-trading-activity-768d87cf95c0.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:10:20", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] KIORA PHARMACEUTICALS INC Insider Trading Activity", "summary": "Kiora Pharmaceuticals' President and CEO, Brian M. Strem, reported a tax-related disposition of 1,869 common shares on July 1, 2026, at a price of $2.66 per share. This transaction was for withholding tax obligations and not an open market sale. Following this adjustment, Strem d", "url": "https://www.stocktitan.net/sec-filings/KPRX/form-4-kiora-pharmaceuticals-inc-insider-trading-activity-a7feaa8def25.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:10:20", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium", "summary": "Kiora Pharmaceuticals announced its participation in the Piper Sandler Virtual Ophthalmology Symposium, featuring an investor fireside chat on July 9, 2026. The clinical-stage biotechnology company focuses on developing advanced therapies for retinal diseases, including KIO-301 f", "url": "https://finance.yahoo.com/healthcare/articles/kiora-pharmaceuticals-participate-piper-sandler-110000041.html", "source_name": "Market source", "published_at": "2026-07-02T18:10:19", "published_display": "02 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora set for Piper Sandler fireside chat on July 9", "summary": "Kiora Pharmaceuticals (NASDAQ:KPRX) will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium on Thursday, July 9, 2026, at 2:30 p.m. EDT. The presentation will be webcast live and a replay will be available for 90 days on Kiora's Investor", "url": "https://www.stocktitan.net/news/KPRX/kiora-pharmaceuticals-to-participate-in-piper-sandler-virtual-ey361aw245yf.html", "source_name": "Stock Titan", "published_at": "2026-07-02T11:12:23", "published_display": "02 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc Warrant 2022-27.09.27 on Kiora Pharma A Financial Disclosures & SEC Filings", "summary": "This page provides access to financial disclosures and SEC filings for Kiora Pharmaceuticals, Inc. (KPHMW), including Forms 10-K, 10-Q, 8-K, and other key documents. The content highlights the company's financial performance, operational updates, clinical trial progress, and corp", "url": "https://www.tradingview.com/symbols/OTC-KPHMW/documents/", "source_name": "TradingView", "published_at": "2026-07-01T22:40:29", "published_display": "01 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPRX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price forecast and current statistics for Kiora Pharmaceuticals, Inc. (KPRX). Analysts have set a price target range of $12.00, with varied recommendations for the stock. The article also covers KPRX's current stock price dynamics, historical highs and low", "url": "https://www.tradingview.com/symbols/NASDAQ-KPRX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T13:10:42", "published_display": "26 Jun 2026 13:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:KPRX)", "summary": "This article provides an overview of Kiora Pharmaceuticals, Inc. (KPRX) stock, including current price, historical performance, analyst forecasts, and financial estimates. It highlights key financial data, such as market capitalization, earnings per share, and net income, and con", "url": "https://www.tradingview.com/symbols/NASDAQ-KPRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:11:41", "published_display": "26 Jun 2026 09:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "7EY Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Kiora Pharmaceuticals, Inc. (7EY) on the Frankfurt Stock Exchange. It details analyst opinions, past performance data, financial reports, and answers frequently asked questions about the company's stock, including earnings, ne", "url": "https://www.tradingview.com/symbols/FWB-7EY/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:45", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc (KPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Kiora Pharmaceuticals Inc (KPRX), detailing its price momentum score of 6.44 and its ranking within the Biotechnology & Medical Research industry. It identifies current support and resistance levels at $2.36 and $2.81, respectively, s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kprx/technical", "source_name": "TradingKey", "published_at": "2026-06-22T12:10:46", "published_display": "22 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX)", "summary": "The article highlights bullish sentiments from analysts on three healthcare stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX), and Luye Pharma Group (LYPHF). Guoyuan Securities (HK) Ltd maintained a Buy rating for Ascentage Pharma with a HK$43.7", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2570678/analysts-are-bullish-on-top-healthcare-stocks-ascentage-pharma-group-international-hk6855-kiora-pharmaceuticals-kprx/", "source_name": "The Globe and Mail", "published_at": "2026-06-21T09:16:56", "published_display": "21 Jun 2026 09:16", "sentiment": "positive", "sentiment_pct": 85, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model", "summary": "Kiora Pharmaceuticals announced preclinical data showing that its ion channel modulator, KIO-300, significantly suppressed seizure activity in an ex vivo temporal lobe epilepsy model. These findings, presented at the Epilepsy Foundation Pipeline Conference, suggest the platform h", "url": "https://ca.finance.yahoo.com/news/kiora-pharmaceuticals-reports-ion-channel-110000045.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-19T12:10:46", "published_display": "19 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPRX SEC Filings - KIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms", "summary": "This page provides access to KIORA PHARMACEUTICALS (KPRX) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-generated summaries and sentiment analysis. Recent filings include the Q3 2025 10-Q reporting a small net income and strong liquidity, and several Schedule 13G/A fi", "url": "https://www.stocktitan.net/sec-filings/KPRX/page-4.html", "source_name": "Stock Titan", "published_at": "2026-06-19T11:39:05", "published_display": "19 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals\u2019 KIO-300 Shows Significant Seizure Suppression in Preclinical Epilepsy Model, Revealing Potential Beyond Ophthalmology 1 \u2013 Minichart", "summary": "Kiora Pharmaceuticals announced significant preclinical results for KIO-300, demonstrating its ability to suppress seizure activity in an ex vivo temporal lobe epilepsy model. These findings suggest KIO-300, initially developed for retinal diseases, has potential in neurological ", "url": "https://www.minichart.com.sg/2026/06/18/kiora-pharmaceuticals-kio-300-shows-significant-seizure-suppression-in-preclinical-epilepsy-model-revealing-potential-beyond-ophthalmology-1/", "source_name": "Minichart", "published_at": "2026-06-18T15:09:15", "published_display": "18 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc (KPRX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Kiora Pharmaceuticals Inc (KPRX), outlining its major shareholders, their proportion of holdings, and institutional investment trends. Key shareholders include Adar1 Capital Management LLC and Stonepine Capital Management, LLC, wh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kprx/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T14:10:38", "published_display": "18 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora's KIO-300 cut epileptiform activity in epilepsy model", "summary": "Kiora Pharmaceuticals (NASDAQ: KPRX) announced preclinical data indicating its ion channel modulator, KIO-300, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model. These findings were presented at the Epilepsy Found", "url": "https://www.stocktitan.net/news/KPRX/kiora-pharmaceuticals-reports-its-ion-channel-modulator-kio-300-r1wyrtnaj3pz.html", "source_name": "Stock Titan", "published_at": "2026-06-18T11:09:15", "published_display": "18 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals (NASDAQ: KPRX) reports KIO-300 epilepsy model data", "summary": "Kiora Pharmaceuticals announced preclinical data for its ion channel modulator, KIO-300, showing it significantly suppressed seizure activity in an ex vivo temporal lobe epilepsy model. This finding suggests potential applications for KIO-300, the active ingredient in its Phase 2", "url": "https://www.stocktitan.net/sec-filings/KPRX/8-k-kiora-pharmaceuticals-inc-reports-material-event-cbb82fe0bb33.html", "source_name": "Stock Titan", "published_at": "2026-06-18T11:09:15", "published_display": "18 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc (KPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Kiora Pharmaceuticals Inc (KPRX) has an earnings forecast score of 8.00, ranking 165 out of 389 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $12.00, indicating a significant upside. The company's expected revenue for the next quar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kprx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:30", "published_display": "18 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc (KPRX) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis of Kiora Pharmaceuticals Inc (KPRX), noting its current valuation score is 8.69, ranking 104 out of 388 in its industry. It highlights the company's P/E ratio of -0.97 but also states that data for P/B, P/S, and P/CF ratios have not yet b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kprx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:15", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc (KPRX) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Kiora Pharmaceuticals Inc (KPRX), which is currently 3.00, unchanged from its previous score. It lists several institutional shareholders and their recent changes in shares held, indicating varying levels of ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kprx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T07:09:15", "published_display": "18 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc (KPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Kiora Pharmaceuticals Inc (KPRX), focusing on business segments and regional contributions. However, it states that relevant data for FY2025 (including Q1, Q2, Q3) and FY2024, FY2021, FY2020, FY2019 have not yet been disclosed by the ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kprx/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T03:40:58", "published_display": "18 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Inc (KPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Kiora Pharmaceuticals Inc (KPRX). It notes that KPRX has not distributed any dividends over the past five years. The article primarily details multiple stock merger events, specifically 9-to-1 mergers in Ju", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kprx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:58", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals (NASDAQ: KPRX) director receives stock options for 25,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNY3JZLXZ1SlY4TFdmdTBqOVd6aTdHNUUxdlVmWExELUZ4azRWUHlBdm50ZkJLMTF1LVZJM2VVRjF0M2V3dmxKbDhEUDJHU2RuN1BkamZsX0hDY0s0eXRsa1lwQ3FBTVByOVU2ZW1OY2N1TXM1LVNKallkNWE5VllWSl9iS1RQbFUxdDVhM2k4YW1Qd3pBT0VTZEJBVTRpcUFabkdGb05WQWFLZ3U2dXJTd3BYSG93d1V3RVA4?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals (KPRX) Slips 4.9% as Stock Tests Key Support Levels - Imbalance Zone", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPRDgtRGdUdDZXb2oxNHJPaFBWMGFzcXU2cWZNWlROcE9pMW5yNThXSnprcWM0STBXNHFyYW1oYS05em44NS1KUlRNY2xhY1RlbjJwVWZNREl4ZzFuaXM2aGU4aHd4bk5PaEpsUUlDMGE5aml6VWZycFJMeG9SR1dVMk5xTXpwMGsxUTVabENxQ25LSVliRXMwbTBKTkZ4SGRESThzWlk3YWtYWkxnOW9wd1BlRGZOMjNHMWc?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals (KPRX) Rallies 5.5%: Key Levels to Watch After Recent Uptick - IV Spike", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOWG1wMnBnRHk4N2Q5UG1MbzQ2dTN6SjNvRVJScG85LTJBRUxnbldLLV8yM2JlQXlwQjJQb1FPR29RSEl1NlFIR1h1dzNfY0FWdGhwSGJPZW5oMW5HZkNOUUtteWtHXzRnNzJHcWJUTGlUY2VwMUFNdTA4ZnBFNGJMekJma1NrdDd6YWFudG91SEk5bDNBdTQxVG1EcG1kTFdkM3hsVVVRZTlWUnJTUkllcEZIa3hXcEhFQjFUSzlR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kiora-pharmaceuticals-reports-first-quarter-110000128.html", "source_name": "TMX Newsfile", "published_at": "2026-05-08T11:00:00+00:00", "published_display": "08 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPbHM0bDg5c3V1OG9iOTFLSUdlNm9CeVVmX25YN0Zvel9HcDhuY3BVSnlVY3lqMFVqYThGSVdvWWxLR3ppeEs0eWFoa0Fhc3Y0R3NUSy14MkR3Mk9hcmdIZGtucmZ3M19Pb2FYODhrbWhURjhmbHMzSGhaY2pYV3hNMExTZVVRWFpaMjF2QVhpZXhWX1cwX3N1QW0zRDAya19MZHhaS1VGRXRrRmZGaDRHc2Frc1dYa292cTFXWnhOV0otdHg0UVFhN1ZCdncteENEbWw2N3NMQ0s?oc=5", "source_name": "TMX Newsfile", "published_at": "2026-04-07T11:12:10+00:00", "published_display": "07 Apr 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals\u2019 Stock Analysis amidst Financial Challenges", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOdjBMNTRHbEZpcG9CbXZHSWtWbjNfZ25tNUZ5T2lCTVI4YTgyTnZJUFdKNmkzX3d2UVFDb3ZZVVBrQUtHc3pVVkRMN0daOUI3emtMQk9tVDl4UUtJWW9iUEJvQWpNdVo1YUYxMzVRSmpQNWZ1Z1ZBRlV2dDI3Z3FGMHgtZzM?oc=5", "source_name": "StocksToTrade", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KPRX Stock Price and Chart \u2014 NASDAQ:KPRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1fS2dxY0tIUmJBXzRZTnlzSml1MGxXQnQwQ3djYlBlamwxcExwS3ppcWtfMlhMaWhRbUdhM1ljRmctS3JiVlNsdFk0b2VVNU9oSEZ1b0o4VnE0M0hR?oc=5", "source_name": "TradingView", "published_at": "2024-06-20T07:00:00+00:00", "published_display": "20 Jun 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQb2Q2bUxmV2lRaWNkUG55R0xHUEJuMlJnTUkzUWZxRzcyYVVnLVhvUWpfWVl2TUFxUU5Fc19sb1ZuYjlGaXY1aUlQUWhOQXhsMjc5RUY3elV2OHI5bTRXVl9BdEtIUjhqbWJCcEZwMDl3dUJGaDFIUno2MWNKVXE2aFFUdkgxc2VNSVEtQjRpUmVJU2FUTF8yZmFnQ0RDV1BmTWVJQ0pDTGpvUXZVUTBwMHd5a3ItRHF2Ny1BS054MG0wdUhiZkE?oc=5", "source_name": "TMX Newsfile", "published_at": "2024-01-31T08:00:00+00:00", "published_display": "31 Jan 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE0wV2trWmVfaWJMMGEzMkNlZGtnbjdVa0Y3aDF4UW5NMU12anhPNENBWFB3a2pIbHhVamV6UDE5ZEtQeE9wT3h1aTQ1Ymt2TldrLUVxVHdtVW8tQQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-11-16T10:15:41+00:00", "published_display": "16 Nov 2021 10:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 45, "sentiment_summary": {"positive": 7, "negative": 5, "neutral": 33, "score": 53, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 12.65, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 2.51, "latest_week": "2026-07-10", "one_week_move": -4.6, "four_week_move": -1.6, "twelve_week_move": -0.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.062219, "market_dynamics_buy_signal": false, "relative_strength": -9.950512, "fair_value_gap": -30.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.4285, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.6% over one week, -1.6% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 10}, {"label": "Stock Titan", "count": 7}, {"label": "TradingKey", "count": 7}, {"label": "Market source", "count": 6}, {"label": "TMX Newsfile", "count": 3}, {"label": "simplywall.st", "count": 2}, {"label": "timothysykes.com", "count": 1}, {"label": "Finviz", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 37}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "37", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-4.6% over one week, -1.6% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. \u2013 LS:A40EG5"}], "updated_at": "2026-07-16T08:05:34.779798+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}